Literature DB >> 30028275

Surgical outcomes of pediatric spinal cord astrocytomas: systematic review and meta-analysis.

Tej D Azad1, Arjun V Pendharkar1, James Pan1, Yuhao Huang1, Amy Li1, Rogelio Esparza1, Swapnil Mehta1, Ian D Connolly1, Anand Veeravagu1, Cynthia J Campen2, Samuel H Cheshier1, Michael S B Edwards1, Paul G Fisher2, Gerald A Grant1.   

Abstract

OBJECTIVE: Pediatric spinal astrocytomas are rare spinal lesions that pose unique management challenges. Therapeutic options include gross-total resection (GTR), subtotal resection (STR), and adjuvant chemotherapy or radiation therapy. With no randomized controlled trials, the optimal management approach for children with spinal astrocytomas remains unclear. The aim of this study was to conduct a systematic review and meta-analysis on pediatric spinal astrocytomas.
METHODS: The authors performed a systematic review of the PubMed/MEDLINE electronic database to investigate the impact of histological grade and extent of resection on overall survival among patients with spinal cord astrocytomas. They retained publications in which the majority of reported cases included astrocytoma histology.
RESULTS: Twenty-nine previously published studies met the eligibility criteria, totaling 578 patients with spinal cord astrocytomas. The spinal level of intramedullary spinal cord tumors was predominantly cervical (53.8%), followed by thoracic (40.8%). Overall, resection was more common than biopsy, and GTR was slightly more commonly achieved than STR (39.7% vs 37.0%). The reported rates of GTR and STR rose markedly from 1984 to 2015. Patients with high-grade astrocytomas had markedly worse 5-year overall survival than patients with low-grade tumors. Patients receiving GTR may have better 5-year overall survival than those receiving STR.
CONCLUSIONS: The authors describe trends in the management of pediatric spinal cord astrocytomas and suggest a benefit of GTR over STR for 5-year overall survival.

Entities:  

Keywords:  GBM = glioblastoma; GTR = gross-total resection; IMSCT = intramedullary spinal cord tumor; OS = overall survival; SEER = Surveillance, Epidemiology, and End Results; STR = subtotal resection; astrocytoma; extent of resection; gross-total resection; intramedullary spinal cord tumor; spine

Mesh:

Year:  2018        PMID: 30028275     DOI: 10.3171/2018.4.PEDS17587

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  4 in total

1.  SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis.

Authors:  Fengping Du; Qian Hou
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

2.  Genomic Landscape of Intramedullary Spinal Cord Gliomas.

Authors:  Ming Zhang; Rajiv R Iyer; Tej D Azad; Qing Wang; Tomas Garzon-Muvdi; Joanna Wang; Ann Liu; Peter Burger; Charles Eberhart; Fausto J Rodriguez; Daniel M Sciubba; Jean-Paul Wolinsky; Ziya Gokaslan; Mari L Groves; George I Jallo; Chetan Bettegowda
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

3.  Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series.

Authors:  Vicki M Butenschoen; Vanessa Hubertus; Insa K Janssen; Julia Onken; Christoph Wipplinger; Klaus C Mende; Sven O Eicker; Victoria Kehl; Claudius Thomé; Peter Vajkoczy; Karl Schaller; Jens Gempt; Bernhard Meyer; Maria Wostrack
Journal:  J Neurooncol       Date:  2020-10-22       Impact factor: 4.130

4.  Development and Validation of a Personalized Prognostic Prediction Model for Patients With Spinal Cord Astrocytoma.

Authors:  Sheng Yang; Xun Yang; Huiwen Wang; Yuelin Gu; Jingjing Feng; Xianfeng Qin; Chaobo Feng; Yufeng Li; Lijun Liu; Guoxin Fan; Xiang Liao; Shisheng He
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.